Platelet‐Lymphocyte ratio is a predictor for the development of no‐reflow phenomenon in patients with ST‐segment elevation myocardial infarction after thrombus aspiration

• Published in: Journal of clinical laboratory analysis Vol. 35; no. 6; pp. e23795 - n/a
• Main Authors: ŞENÖZ, Oktay, EMREN, Sadık Volkan, ERSEÇGİN, Ahmet, YAPAN EMREN, Zeynep, GÜL, İlker
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.06.2021; John Wiley and Sons Inc
• Subjects: Angioplasty; Blood clots; Blood platelets; Blood Platelets - pathology; Cardiovascular disease; Catheters; Coronary vessels; Creatinine; Diabetes; Ejection fraction; Enzymes; Female; Follow-Up Studies; Glycoproteins; Heart attacks; Heart failure; Humans; Laboratories; Lymphocytes; Lymphocytes - pathology; Male; manual thrombus aspiration; Medical imaging; Middle Aged; Mortality; Myocardial infarction; no reflow; No-Reflow Phenomenon - diagnosis; No-Reflow Phenomenon - etiology; Percutaneous Coronary Intervention - adverse effects; platelet to lymphocyte ratio; Platelets; primary percutaneous coronary intervention; Prognosis; Regression analysis; Retrospective Studies; ST Elevation Myocardial Infarction - therapy; Standard deviation; Statistical analysis; ST‐segment elevation myocardial infarction; Suction - adverse effects; Thrombolysis; Thrombosis; Thrombosis - physiopathology; Variables; manual thrombus aspiration; no reflow; platelet to lymphocyte ratio; ST-segment elevation myocardial infarction; primary percutaneous coronary intervention
• ISSN: 0887-8013; 1098-2825
• DOI: 10.1002/jcla.23795

Backround We aimed to evaluate the utility of the preprocedural platelet–lymphocyte ratio (PLR) for predicting the no‐reflow phenomenon after thrombus aspiration during percutaneous coronary intervention (PCI) in patients with ST‐segment elevation myocardial infarction (STEMI). Method We retrospectively analyzed postprocedural thrombolysis in myocardial infarction (TIMI) flow grades and myocardial blush grades (MBG) of 247 patients who underwent a PCI procedure with thrombus aspiration.We divided these patients into two groups according to whether they had no‐reflow (TIMI < 3, MBG < 2) or not (TIMI 3, MBG ≥ 2). Results No‐reflow developed in 43 (17%) patients.Preprocedural PLR was significantly higher in the no‐reflow group (183.76 ± 56.65 vs 118.32 ± 50.42 p < 0.001).Independent predictors of no‐reflow were as follows: higher preprocedural platelet‐lymphocyte ratio (PLR) (OR = 1.018; 95% CI = 1.004, 1.033; p = 0.013),mean corpuscular volume (MCV) (OR = 1.118; 95% CI = 1.024, 1.220; p = 0.012) and SYNTAX Score‐2 (OR = 1.073; 95% CI = 1.005, 1.146; p = 0.036). PLR of 144 had 79% sensitivity and 75% specificity for the prediction of no‐reflow. Conclusion PLR is a reliable predictor for no‐reflow in STEMI patients undergoing thrombus aspiration. No reflow developed in 43 (17%) of 247 patients who underwent thrombus aspiration during the PCI procedure.Independent predictors of no‐reflow were found as follows;higher preprocedural platelet‐lymphocyte (PLR),mean corpuscular volüme (MCV) and SYNTAX Score‐2.PLR > 144 had 79% sensitivity and 75% specificity for determining no‐reflow phenomenon.